Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. The Company is focused specifically on advance artificial intelligence and machine learning (AI/ML)- driven analysis of complex datasets in medicine and healthcare. The Company's objective is to use its AI/ML platform to provide a precision-medicine approach to drug-asset enablement through external partnerships and selective internal development.
Last trade$0.4305
Day change-$0.0573 (-11.75%)
Day range$0.411 – $0.519
Volume230,485
Market cap$9M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$9.16M
Price / earnings
—
Price / book
1.8×
Price / sales
32.83×
EV / sales
14.95×
EV / EBITDA
-0.63×
Profitability
Earnings per share
-$0.35
Return on assets
-111.43%
Return on equity
-127.22%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
7.75×
Quick ratio
7.75×
Cash ratio
6.94×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$6.28M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BFRG, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$63.58K
$215.39K
$0
$0
$83.41K
$33.26K
$0
$0
Cost of revenue
$53.54K
$108.49K
$0
$0
$68.04K
$26.74K
$0
$0
Gross profit
$10.04K
$106.9K
$0
$0
$15.37K
$6.52K
$0
$0
Selling, general and administrative
$1.62M
$1.19M
$1.18M
$1.1M
$1.24M
$995.9K
$1.48M
$1.18M
Research and development
$439.24K
$339.46K
$434.82K
$397.19K
$345.99K
$480.3K
$576.26K
$590.86K
Total operating expenses
$2.06M
$1.53M
$1.61M
$1.5M
$1.59M
$1.48M
$2.06M
$1.77M
Operating income
-$2.05M
-$1.42M
-$1.61M
-$1.5M
-$1.57M
-$1.47M
-$2.06M
-$1.77M
Interest expense
-$1.5K
-$2.37K
-$982
-$622
-$1.54K
-$2.45K
-$1.02K
-$2.01K
Income before taxes
-$2.01M
-$1.37M
-$1.59M
-$1.48M
-$1.55M
-$1.45M
-$2.02M
-$1.71M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$2.01M
-$1.37M
-$1.59M
-$1.48M
-$1.55M
-$1.45M
-$2.02M
-$1.71M
Net income attributable to common shareholders
-$2.01M
-$1.37M
-$1.59M
-$1.48M
-$1.55M
-$1.45M
-$2.02M
-$1.74M
EBITDA
-$2.05M
-$1.42M
-$1.61M
-$1.5M
-$1.57M
-$1.47M
-$2.06M
-$1.77M
Basic earnings per share
-$0.11
-$0.07
-$0.12
-$0.13
-$0.15
-$0.15
-$0.21
-$0.19
Diluted earnings per share
-$0.11
-$0.07
-$0.12
-$0.13
-$0.15
-$0.15
-$0.21
-$0.19
Recent news
Company coverage with links to the original publishers.
Bullfrog AI Holdings Inc. (BFRG) reported a Q3 loss of $0.11 per share, missing consensus estimates of $0.09 loss by 22.22%. Revenue came in at $0.06 million, missing estimates by 71.1%. The stock has declined 37.4% year-to-date and received a Zacks Rank #3 (Hold) rating, expected to perform in line with the market.
Assembly Biosciences reported a quarterly loss of $0.93 per share, significantly worse than the consensus estimate of $0.44, representing a -111.36% earnings surprise. Revenue also missed expectations at $2.96 million versus consensus. The stock has declined 34.2% year-to-date and carries a Zacks Rank #3 (Hold) rating, expected to perform in line with the market.
Carlsmed, Inc. (CARL) reported a quarterly loss of $0.34 per share, beating consensus estimates of $0.42 loss, with a 19.05% earnings surprise. Revenue reached $21.55 million, surpassing estimates by 10.06% and up 64.8% year-over-year. The stock has gained 30% year-to-date versus the S&P 500's 10.3% gain. However, the company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
BullFrog AI Holdings, Inc. (NASDAQ: BFRG) announced the launch of bfARENAS™, a scenario-based decision engine designed to help biotech and pharmaceutical companies optimize drug portfolio strategy and clinical trial design. The new tool completes the company's end-to-end AI intelligence workflow by enabling head-to-head comparison of drug programs across multiple strategic scenarios, addressing the industry challenge where approximately 90% of clinical trials fail due to inefficient capital deployment and lack of structured decision-making frameworks.
ProFound Therapeutics appointed Tom Chittenden as Chief Technology Officer and Laurel Ostrom as Chief Human Resources Officer to enhance their AI-driven drug discovery platform and organizational capabilities.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.